OPGN - Kapitalisasi marang volume dodolan OpGen Inc
OpGen, Inc. (OPGN) management is facing a prolonged crisis due to a severe shortage of funds. Business revenues are based on the sale of Acuitas molecular tests to hospitals. The company's revenue valuation on the GURU.Markets terminal analytical chart clearly demonstrates the trend, where the 6.10 mark shows the current state. However, bankruptcy risk and the slow implementation of diagnostics threaten the very existence of the enterprise.
Rincian metrik lan analitis perusahaan OpGen Corp (OPGN)
The price-to-sales ratio allows for an assessment of the market value of a single dollar of revenue, determining the margin of safety and the risk of capital stagnation. For OpGen, Inc. (OPGN), which develops rapid tests against superbugs, median P/S analysis helps align expansion rates within the hospital segment with the asset's current valuation, classifying it as a speculative instrument with high growth potential.
